Literature DB >> 34026222

Laparoscopic gastrectomy for elderly gastric-cancer patients: comparisons with laparoscopic gastrectomy in non-elderly patients and open gastrectomy in the elderly.

Zheng-Yan Li1,2, Jie Chen1, Bin Bai1, Shuai Xu1, Dan Song1, Bo Lian1, Ji-Peng Li1, Gang Ji1, Qing-Chuan Zhao1.   

Abstract

BACKGROUND: The benefits of laparoscopic gastrectomy (LG) in elderly gastric-cancer patients still remain unclear. The purpose of this study was to evaluate the feasibility and safety of LG in elderly gastric-cancer patients.
METHODS: We retrospectively evaluated patients who underwent LG or open gastrectomy (OG) between June 2009 and July 2015 in a single high-volume center. We compared surgical, short-term, and long-term survival outcomes among an elderly (≥70 years old) LG (ELG) group (n = 114), a non-elderly (<70 years old) LG (NLG) group (n = 740), and an elderly OG (EOG) group (n = 383).
RESULTS: Except for extended time to first flatus, the surgical and short-term outcomes of the ELG group were similar to those of the NLG group. The ELG group revealed comparable disease-specific survival (DSS) rates to the NLG group (64.9% vs 66.2%, P = 0.476), although the overall survival (OS) rate was lower (57.0% vs 65.5%, P < 0.001) in the ELG group than in the NLG group. The ELG group showed longer operation time than the EOG group (236.4 ± 77.3 vs 179 ± 52.2 min, P < 0.001). The ELG group had less estimated blood loss (174.0 ± 88.4 vs 209.3 ± 133.8, P = 0.008) and shorter post-operative hospital stay (8.3 ± 2.5 vs 9.2 ± 4.5, P = 0.048) than the EOG group. The severity of complications was similar between the ELG and NLG groups. Multivariate analysis confirmed that LG was not a risk factor for post-operative complications.
CONCLUSIONS: LG is a feasible and safe procedure for elderly patients with acceptable short- and long-term survival outcomes.
© The Author(s) 2020. Published by Oxford University Press and Sixth Affiliated Hospital of Sun Yat-sen University.

Entities:  

Keywords:  elderly patients; gastric cancer; laparoscopic gastrectomy

Year:  2020        PMID: 34026222      PMCID: PMC8128003          DOI: 10.1093/gastro/goaa041

Source DB:  PubMed          Journal:  Gastroenterol Rep (Oxf)


Introduction

Laparoscopic gastrectomy (LG) has been increasingly performed since it was first reported in 1994 by Kitano et al. [1]. Based on the experience accumulation of LG for early-stage gastric cancer, some experienced surgeons in high-volume centers have applied the laparoscopic procedure for patients with locally advanced gastric cancer (AGC) [2-7]. Recently, the results of several multicenter randomized–controlled trials (RCTs) showed that LG is a safe and feasible surgical procedure for AGC in short- and long-term outcomes [8-12]. With the rapid aging of the global population, the number of elderly patients has been continuously increasing. In China, elderly patients account for one-third of patients with gastric cancer [13]. Elderly patients are often considered a high-risk population for gastrectomy due to the high proportion of upper gastric cancer, advanced tumor stage, reduced functional reserve, and increased co-morbidities [14-17]. Therefore, elderly patients are always given more attention in the perioperative period than the non-elderly population. LG has been gradually accepted by more and more elderly patients, although the effects of pneumoperitoneum during LG are still in debate [18, 19]. To date, the feasibility of LG in elderly patients remains controversial [20, 21]. Research on the application of LG in elderly patients is lacking. To evaluate the safety and feasibility of LG in elderly patients, we compared the surgical and long-term survival outcomes with those for LG in younger patients and with those for OG in elderly patients.

Patients and methods

Patients

We selected patients who underwent LG and open gastrectomy (OG) at Xijing Hospital of Digestive Diseases, Fourth Military Medical University (Xi’an, China) between June 2009 and July 2015 in a prospectively maintained gastric-cancer database. As the OG was mainly performed before 2016, we limited the duration of study. Pathologic staging was updated according to the 8th Union for International Cancer Control (UICC)/American Joint Committee on Cancer staging system of gastric cancer [22]. The inclusion criteria for this study were as follows: pathologically confirmed gastric adenocarcinoma, an R0 resection, post-operative pathological stage I to III diseases, not combined with other malignancy, no prior surgery for gastric cancer, and no neoadjuvant chemotherapy. Finally, this study included 854 patients in the LG group and 383 elderly patients in the OG group. We categorized the patients by age: elderly (≥70 years old) and non-elderly (<70 years old). Among the patients who underwent LG, 114 patients were assigned to the elderly LG (ELG) group and 740 patients were in the non-elderly LG (NLG) group; 383 patients were in the elderly OG (EOG) group. This study was approved by the Institutional Review Board of our institution.

Definition of co-morbidities

We divided the co-morbid diseases into seven categories: respiratory disease (chronic obstructive pulmonary disorder, interstitial pneumonia, asthma, spirometry abnormality), diabetes (controlled by medication or insulin), hypertension (controlled by medication), cardiovascular disease (coronary artery disease, cardiomyopathy, arrhythmia, past history of cardiac surgery or catheter intervention), cerebrovascular disease (brain infarction, neurodegenerative disease), liver disease (chronic hepatitis B/C, liver cirrhosis, hepatocellular carcinoma), and renal disease (chronic renal disease).

Surgical procedures

The procedures for LG and OG have been previously described in detail [23-25]. All surgeries were performed by surgeons experienced in LG and OG. Patients chose the surgical types individually after they were informed of the surgical, complication, and oncological risks. We routinely administered post-operative adjuvant chemotherapy with 5-fluorouracil and cisplatin to each patient with stage II or more advanced cancer.

Post-operative evaluation and follow-up

The primary endpoint was post-operative complication. The secondary endpoints were 5-year overall survival (OS) rate and 5-year disease-specific survival (DSS) rate. The OS period were defined as the interval between the date of operation to the date of death for any cause or the last follow-up. The DSS period was defined as the interval between the date of operation and the date of death due to gastric cancer or the last follow-up. Post-operative complications that occurred within 30 days after surgery were recorded and classified according to the Clavien–Dindo classification [26, 27]. Patients were followed up every 3 months during the first 2 years, every 6 months from 3 to 5 years, and then annually. The last follow-up date was July 2018.

Statistical analysis

All statistical analyses were performed using SPSS, ver.22.0 (SPSS Inc., Chicago, IL, USA). The chi-square test was used to compare categorical variables and the independent sample t-test or Mann–Whitney U test was used to compare continuous variables. Multivariate analysis was conducted with the binary logistic-regression model to identify independent risk factors for post-operative complications. Survival curves were calculated using the Kaplan–Meier method and analysed by the log-rank test. All values were two-tailed and P-values <0.05 were considered significant.

Results

Clinicopathological characteristics

Table 1 summarizes the clinicopathological characteristics of the three groups. The ELG group showed higher ASA scores than the NLG group (P < 0.001). Moreover, patients in the ELG group presented with more co-morbidity than those in the NLG group (P < 0.001). No significant differences were observed between the ELG and the NLG groups in patient characteristics such as age, sex, body mass index, histological type, extent of resection, and TNM stage. The patient characteristics were comparable between the ELG and EOG groups.
Table 1.

Baseline demographic and clinical characteristics of patients in the ELG, NLG, and EOG groups

VariablesELG (n = 114)NLG (n = 740) P EOG (n = 383) P

Agea, years

74.2 ± 3.9

55.9 ± 8.5

<0.001

73.9 ± 3.4

0.455

Sex

0.470

0.801

 Male

85 (74.6)

576 (22.2)

290 (75.7)

 Female

29 (25.4)

164 (77.8)

93 (24.3)

BMIa, kg/m2

22.4 ± 3.2

22.8 ± 8.7

0.622

22.0 ± 3.0

0.190

ASA grade

0.001

0.768

 1–2

67 (58.8)

661 (89.3)

231 (60.3)

 3

47 (41.2)

79 (10.7)

152 (39.7)

Histological type

0.111

0.103

 Differentiated

46 (40.4)

242 (32.7)

123 (32.1)

 Undifferentiated

68 (59.6)

498 (67.3)

260 (67.9)

Extent of resection

0.686

0.196

 DG

49 (43.0)

335 (45.3)

139 (36.3)

 TG

65 (57.0)

405 (54.7)

244 (63.7)

pTNM stage

0.545

0.282

 I

35 (30.7)

195 (26.4)

90 (23.5)

 II

32 (28.1)

204 (27.6)

125 (32.6)

 III

47 (41.2)

341 (46.1)

168 (43.9)

Co-morbidity

41 (36.0)

125 (16.9)

0.001

126 (32.9)

0.543

Respiratory disease

29 (25.4)

31 (4.2)

< 0.001

91 (23.8)

0.807

Diabetes

12 (10.5)

44 (5.9)

0.066

34 (8.9)

0.727

 Hypertension

15 (13.2)

35 (4.7)

< 0.001

58 (15.1)

0.708

 Cardiovascular disease

10 (8.8)

17 (2.3)

< 0.001

31 (8.1)

0.970

 Cerebrovascular disease

9 (7.9)

6 (0.8)

< 0.001

29 (7.6)

0.931

 Liver disease

3 (2.6)

5 (0.7)

0.134

1 (3.4)

0.959

 Renal disease

2 (1.8)

3 (0.4)

0.272

8 (2.1)

0.875

 Other

2 (1.8)

4 (0.5)

0.400

7 (1.8)

0.959

Except for these variables, other values are presented as numbers of patients followed by percentages in parentheses. ELG, elderly laparoscopic gastrectomy; NLG, non-elderly group; EOG, elderly open group; DG, distal gastrectomy; TG, total gastrectomy.

Baseline demographic and clinical characteristics of patients in the ELG, NLG, and EOG groups Age, years 74.2 ± 3.9 55.9 ± 8.5 <0.001 73.9 ± 3.4 0.455 Sex 0.470 0.801 Male 85 (74.6) 576 (22.2) 290 (75.7) Female 29 (25.4) 164 (77.8) 93 (24.3) BMI, kg/m2 22.4 ± 3.2 22.8 ± 8.7 0.622 22.0 ± 3.0 0.190 ASA grade 0.001 0.768 1–2 67 (58.8) 661 (89.3) 231 (60.3) 3 47 (41.2) 79 (10.7) 152 (39.7) Histological type 0.111 0.103 Differentiated 46 (40.4) 242 (32.7) 123 (32.1) Undifferentiated 68 (59.6) 498 (67.3) 260 (67.9) Extent of resection 0.686 0.196 DG 49 (43.0) 335 (45.3) 139 (36.3) TG 65 (57.0) 405 (54.7) 244 (63.7) pTNM stage 0.545 0.282 I 35 (30.7) 195 (26.4) 90 (23.5) II 32 (28.1) 204 (27.6) 125 (32.6) III 47 (41.2) 341 (46.1) 168 (43.9) Co-morbidity 41 (36.0) 125 (16.9) 0.001 126 (32.9) 0.543 Respiratory disease 29 (25.4) 31 (4.2) < 0.001 91 (23.8) 0.807 Diabetes 12 (10.5) 44 (5.9) 0.066 34 (8.9) 0.727 Hypertension 15 (13.2) 35 (4.7) < 0.001 58 (15.1) 0.708 Cardiovascular disease 10 (8.8) 17 (2.3) < 0.001 31 (8.1) 0.970 Cerebrovascular disease 9 (7.9) 6 (0.8) < 0.001 29 (7.6) 0.931 Liver disease 3 (2.6) 5 (0.7) 0.134 1 (3.4) 0.959 Renal disease 2 (1.8) 3 (0.4) 0.272 8 (2.1) 0.875 Other 2 (1.8) 4 (0.5) 0.400 7 (1.8) 0.959 Except for these variables, other values are presented as numbers of patients followed by percentages in parentheses. ELG, elderly laparoscopic gastrectomy; NLG, non-elderly group; EOG, elderly open group; DG, distal gastrectomy; TG, total gastrectomy.

Surgical outcomes

Table 2 shows the details of the surgical outcomes and post-operative complications of the three groups. The ELG and NLG groups showed no significant differences in operation time, estimated blood loss, number of retrieved lymph nodes, and post-operative hospital stay (all P > 0.05). The time from operation to first flatus in the NLG group was shorter than that in the ELG group. Compared with the EOG group, the ELG group showed longer operation time (236.4 ± 77.3 vs 179.7 ± 52.2 min, P = 0.001). The estimated blood loss (174.0 ± 88.4 vs 209.3 ± 133.8, P = 0.008) and post-operative hospital stay (8.3 ± 2.5 vs 9.2 ± 4.5, P = 0.048) were decreased in the ELG group compared with those in the EOG group. There were no significant differences in the number of retrieved lymph nodes between the ELG and NLG groups. However, the time from operation to first flatus was shorter in the ELG group than in the EOG group, although the difference was not statistically significant (3.9 ± 1.2 vs 4.2 ± 1.0, P = 0.074).
Table 2.

Surgical and short-term outcomes of patients in the ELG, NLG, and EOG groups

VariablesELG (n = 114)NLG (n = 740) P EOG (n = 383) P
Operation time, min236.4 ± 77.3231.5 ± 76.10.523179.7 ± 52.20.001
Estimated blood loss, mL174.0 ± 88.4169.8 ± 106.80.696209.3 ± 133.80.008
Lymph-node dissection, n (%)0.7410.277
 D1/D1+21 (18.4)127 (17.2)89 (23.2)
 D293 (81.6)613 (82.8)294 (76.8)
No. of retrieved lymph nodes23.4 ± 7.724.3 ± 7.80.22724.1 ± 9.70.440
Time to first flatus, days3.9 ± 1.22.9 ± 1.4<0.0014.2 ± 1.00.074
Post-operative hospital stay, days8.3 ± 2.57.5 ± 4.80.0839.2 ± 4.50.048
Post-operative complication, n (%)
 Wound problem2 (1.8)12 (1.6)1.00013 (3.4)0.538
 Pulmonary complication14 (12.3)55 (7.4)0.07750 (13.1)0.829
 Intra-abdominal abscess4 (3.5)16 (2.2)0.3276 (1.6)0.248
 Intra-abdominal bleeding2 (1.8)15 (2.0)1.0008 (2.1)1.000
 Anastomotic leakage5 (4.4)19 (2.6)0.3548 (2.1)0.187
 Bowel obstruction1 (0.9)15 (2.0)0.71010 (2.6)0.470
 Hepatic2 (1.8)5 (0.7)0.2372 (0.5)0.227
 Cardiac0 (0.0)2 (0.3)1.0003 (0.8)1.000
Overall complications (%)20 (17.5)89 (12.0)0.13083 (21.7)0.340
Clavien–Dindo classification, n (%)0.9200.983
 Grade II14 (12.3)65 (8.8)56 (14.6)
 Grade III3 (2.6)14 (1.9)12 (3.1)
 Grade IV2 (1.8)8 (1.1)11 (2.9)
 Grade V1 (0.9)2 (0.3)4 (1.0)
Clavien–Dindo grade III/IV, n (%)6 (5.3)24 (3.2)0.27327 (7.0)0.501

ELG, elderly laparoscopic gastrectomy; NLG, non-elderly group; EOG, elderly open group; D1 (TG: Nos. 1–7; DG: D1: Nos. 1–7); D1+ (TG: Nos. 1–8a, 9, 11p; DG: No. 1, 3, 4sb, 4d, 5, 6, 7, 8a, 9); D2 (TG: Nos. 1–8a, 9, 10, 11p, 11d, 12a; DG: No. 1, 3, 4sb, 4d, 5, 6, 7, 8a, 9, 11p, 12a).

Surgical and short-term outcomes of patients in the ELG, NLG, and EOG groups ELG, elderly laparoscopic gastrectomy; NLG, non-elderly group; EOG, elderly open group; D1 (TG: Nos. 1–7; DG: D1: Nos. 1–7); D1+ (TG: Nos. 1–8a, 9, 11p; DG: No. 1, 3, 4sb, 4d, 5, 6, 7, 8a, 9); D2 (TG: Nos. 1–8a, 9, 10, 11p, 11d, 12a; DG: No. 1, 3, 4sb, 4d, 5, 6, 7, 8a, 9, 11p, 12a).

Post-operative complication

The overall post-operative complication rate in the ELG group did not differ from that in the NLG group (17.5% vs 12.0%, P = 0.130). The severity of complications in the ELG group was also comparable to that in the NLG group in the severe-complication (Clavien–Dindo grade ≥IIIa) rate (5.3% vs 3.2%, P = 0.273). We also observed no significant difference between the ELG and EOG groups in overall- and severe-complication rates (17.5% vs 21.7%, P = 0.340; 5.3% vs 7.0%, P = 0.501, respectively).

Analysis of risk factors for post-operative complications

Multivariate analysis showed that pathological stage [odds ratio (OR), 1.854; 95% confidential interval (CI), 1.071–3.210, P = 0.027] was an independent risk factor for overall complications after LG, but age was not (Table 3). For elderly patients, longer operation time (OR, 2.179; 95% CI, 1.206–3.937, P = 0.010) and total gastectomy (OR, 1.714; 95% CI, 1.047–2.805, P = 0.032) were independent risk factors for overall complications. Regarding severe complications, estimated blood loss >200 mL (OR, 3.208; 95% CI, 1.248–8.248, P = 0.016) was identified as an independent risk factor in the LG group. Among elderly patients, longer operation time (OR, 2.734; 95% CI, 1.089–6.860, P = 0.032) was shown as an independent risk factor for severe complications.
Table 3.

Multivariate logistic-regression analysis of risk factors for post-operative complications

VariablesOverall complications
Severe complications
LG in elderly and non-elderly
LG and OG in elderly
LG in elderly and non-elderly
LG and OG in elderly
OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
Surgical procedure, OG vs LG0.778 (0.450–1.344)0.3680.754 (0.296–1.925)0.555
Age, Non-elderly vs Elderly1.480 (0.836–2.620)0.1791.583 (0.595–4.213)0.358
Sex, Male vs Female0.833 (0.502–1.382)0.8330.943 (0.558–1.595)0.8270.532 (0.181–1.562)0.2510.426 (0.144–1.262)0.124
BMI, kg/m2 , <24 vs ≥240.989 (0.628–1.555)0.9601.411 (0.870–2.288)0.8270.970 (0.428–2.200)0.9420.800 (0.341–1.877)0.608
ASA, 1–2 vs 31.106 (0.624–1.963)0.7300.999 (0.635–1.572)0.9980.988 (0.351–2.780)0.9821.428 (0.685–2.974)0.342
Operation time, min, <240 vs ≥2400.826 (0.436–1.564)0.5572.179 (1.206–3.937)0.0100.710 (0.195–2.588)0.6042.734 (1.089–6.860)0.032
Estimated blood loss, mL, <200 vs ≥2001.128 (0.734–1.733)0.5831.217 (0.767–1.931)0.4053.208 (1.248–8.248)0.0161.352 (0.622–2.937)0.446
Histological type, Differentiated vs Undifferentiated0.832 (0.534–1.297)0.8320.969 (0.605–1.552)0.8950.891 (0.394–2.012)0.7811.301 (0.582–2.909)0.521
Extent of resection, DG vs TG1.066 (0.694–1.638)0.7711.714 (1.047–2.805)0.0321.991 (0.849–4.671)0.1132.050 (0.868–4.840)0.102
pTNM stage, I vs II–III1.854 (1.071–3.210)0.0270.909 (0.538–1.535)0.7201.656 (0.588–4.661)0.3400.458 (0.207–1.012)0.054
Co-morbidity, No vs Yes1.290 (0.779–2.136)0.3221.349 (0.850–2.139)0.2041.466 (0.616–3.491)0.3872.528 (1.206–5.298)0.014

DG, distal gastrectomy; TG, total gastrectomy; OR, odds ratio; CI, confidential interval.

Multivariate logistic-regression analysis of risk factors for post-operative complications DG, distal gastrectomy; TG, total gastrectomy; OR, odds ratio; CI, confidential interval.

Long-term survival

The 5-year OS rate was significantly lower in the ELG group than in the NLG group (57.0% vs 65.5%, P < 0.001, Figure 1), whereas the DSS rate of the ELG group was similar to that of the NLG group (64.9% vs 66.2%, P = 0.476, Figure 2). The 5-year OS and DSS rates were similar between the ELG and EOG groups (57.0% vs 56.7%, P = 0.753, Figure 1A; 64.9% vs 60.6%, P = 0.377, Figure 1B). The stage-specific analysis showed that the 5-year OS rate was significantly lower in the ELG group than that in the NLG group in stage II gastric cancer, whereas the 5-year OS rate of the ELG group was similar to that of the NLG group for stage I or III gastric cancer (Figure 2). Three groups showed similar DSS rates for stage I to III gastric cancer (Figure 3).
Figure 1.

Kaplan–Meier OS and DSS curves for the ELG, NLG, and EOG groups. (A) OS; (B) DSS.

Figure 2.

Kaplan–Meier overall survival curves for the ELG, NLG, and EOG groups. (A) Stage I gastric cancer; (B) stage II gastric cancer; (C) stage III gastric cancer.

Figure 3.

Kaplan–Meier disease-specific survival curves for the ELG, NLG, and EOG groups. (A) Stage I gastric cancer; (B) stage II gastric cancer; (C) stage III gastric cancer.

Kaplan–Meier OS and DSS curves for the ELG, NLG, and EOG groups. (A) OS; (B) DSS. Kaplan–Meier overall survival curves for the ELG, NLG, and EOG groups. (A) Stage I gastric cancer; (B) stage II gastric cancer; (C) stage III gastric cancer. Kaplan–Meier disease-specific survival curves for the ELG, NLG, and EOG groups. (A) Stage I gastric cancer; (B) stage II gastric cancer; (C) stage III gastric cancer.

Discussion

This study found that the short-term outcomes of the ELG group were better than those of the EOG group. Meanwhile, ELG group showed similar post-operative outcomes to those of patients in the EOG group in the incidence and severity of post-operative complications based on Clavien–Dindo classification. Moreover, no significant differences in the 5-year OS and DSS rates were found between the ELG and EOG groups. Elderly patients are often considered a high-risk population for gastrectomy due to the high proportion of upper gastric cancer, more advanced tumor stage, reduced functional reserve, and increased co-morbidities [14-16]. Extensive research has shown that LG has the advantages of smaller incision, less bleeding, alleviated pain, and decreased surgical stress [28-30]. Elderly patients are at high risk of post-operative complications due to reduced functional reserve and increased co-morbidities. A recent meta-analysis demonstrated that elderly patients with gastric cancer who underwent LG had a higher overall post-operative complication rate than the non-elderly patients [31]. Kubota et al. [32] and Tokunaga et al. [33] found that post-operative complications had a negative effect on OS outcome even if the tumor underwent radical resection. We also found a similar phenomenon recently [34]. Moreover, our results showed that the negative effects were increased with higher Clavien–Dindo grades [35]. In the present study, although elderly patients tended to have higher ASA scores and more co-morbidities, the overall complication rate and severity of post-operative complications in the ELG group were similar with those in the NLG group. Prolonged operation time and carbon-dioxide pneumoperitoneum during the surgical procedure are major concerns during LG for elderly patients, who exhibit higher rates of cardiovascular and pulmonary co-morbidities that can be adversely affected by longer anesthesia and pneumoperitoneum [9, 18, 19]. Longer operation time was always reported as a drawback of LG that acts as an negative factor for surgical outcomes [36]. In the current study, the mean operation time in the ELG group was significantly longer than that in the EOG group. A recent multicenter RCT reported that the mean operation time of the LG group was ∼30 min longer than that of the OG group, even when the surgeries were performed by experienced surgeons. Miki et al. [37] demonstrated that patients with longer operation time were associated with a higher risk of severe post-operative complications. In this study, multivariate analysis showed that extended operation time was an independent risk factor for the occurrence of severe complications in the elderly group. Additionally, LG was not identified as a risk factor for overall and severe complications, which is similar to the previous studies comparing the clinical outcomes of LG and OG for elderly gastric-cancer patients [20, 38]. Wang et al. [39] found that, for patients, combined pulmonary disease was a predictive factor for the occurrence of systemic complications after LG. Cho et al. [40] also reported that elderly patients with preoperative pulmonary diseases were associated with higher incidence of post-operative respiratory complications after LG. However, these results did not indicate that LG increases the incidence of post-operative respiratory complications for patients with preoperative pulmonary diseases. Suzuki et al. [18] found that cardiopulmonary impairment caused by carbon-dioxide pneumoperitoneum was transitory and could normalize during the intraoperative period. In the current study, our results showed that the pulmonary-complication rates between the ELG group and the EOG group were similar, which is consistent with the results reported in previous studies conducted by Zheng et al. [41] and Lu et al. [38]. To date, several studies have demonstrated that LG is a safe and feasible procedure for the treatment of elderly gastric-cancer patients [16, 21, 41, 42]. However, the primary endpoints of previous studies were mainly focused on short-term outcomes and therefore the long-term survival outcomes were seldom investigated. Regarding the effect of survival in elderly patients, Zheng et al. [41] reported similar 2-year OS rates between the LG and OG groups. Shimada et al. [20] demonstrated that LG could be a curative therapy procedure for elderly gastric-cancer patients in the comparison of 5-year DSS rates between elderly and non-elderly groups. In the current study, the 5-year OS rate of patients in the ELG group was lower than that in the NLG group. In China, the average lifespans of men and women are 74 and 77 years, respectively [43]. Based on this situation, elderly patients always died of causes other than gastric cancer. In this study, the DSS rate of patients in the elderly group was comparable to that in the non-elderly group. Moreover, the OS and DSS survival rates were similar between the two elderly groups. These results suggest that LG can be a safe procedure for elderly gastric patients in terms of long-term survival outcomes. The number of retrieved lymph nodes is considered a key indicator of the quality of gastrectomy for gastric-cancer patients. Gastrectomy with D2 lymphadenectomy is standard in the treatment of locally AGC [44]. However, the reasonable extent of lymphadenectomy for elderly gastric-cancer patients still remains controversial. For these cases, some surgeons are usually reluctant to perform D2 resection because of the concerns of the potentially increased morbidity. Rausei et al. [45] found no significant benefits of D2 over D1 for patients >70 years old, although it showed the benefits in OS and DSS rates when the overall age band was taken into consideration. Takeshita et al. [46] demonstrated that limited lymph-node dissection had no negative effect for the DSS rates of elderly gastric patients. In this study, elderly patients with stage II or III disease account for 74.8% and a high percentage of D2 lymphadenectomies were performed. In contrast with several previous studies, our results showed no significant difference between the ELG group and the NLG group in the comparison of the number of retrieved lymph nodes and extent of lymphadenectomy. Previous studies with the purpose of evaluating the role of lymphadenectomy in elderly gastric-cancer patients had the limitations of small sample sizes and a retrospective nature. Therefore, large multicenter prospective RCTs should be conducted to further investigate the optimal extent of lymph-node dissection in elderly patients. Several limitations of this study should be acknowledged. First, the post-operative complications are limited to grades II–V. This study did not consider complications in grade I, which was always not recorded in our clinical practice. Additionally, this is a retrospective study conducted in a high-volume center in China and all surgeries were performed by experienced surgeons, which may limit the applicability of our results to other centers and populations. In conclusion, this study demonstrated that LG is a feasible and safe procedure for elderly gastric-cancer patients with acceptable short- and long-term outcomes. The results of this study need to be further validated by multicenter RCT studies.

Authors’ contributions

ZYL, JC and QCZ designed the study. BB, SX and DS performed the research and retrieved the data. JPL, GJ and BL analyzed the data. ZYL and JC drafted the paper. All authors read and approved the final manuscript.

Funding

This study was supported by the National Key Research and Development Program of China [2017YFC1311004] and The Key Research and Development Program of Shanxi province [2017-ZDXM-SF-053].
  46 in total

1.  The impact of comorbidity on surgical outcomes in laparoscopy-assisted distal gastrectomy: a retrospective analysis of multicenter results.

Authors:  Wook Kim; Kyo Young Song; Hyuk-Joon Lee; Sang Uk Han; Woo Jin Hyung; Gyu Seok Cho
Journal:  Ann Surg       Date:  2008-11       Impact factor: 12.969

2.  Morbidity and Mortality of Laparoscopic Versus Open D2 Distal Gastrectomy for Advanced Gastric Cancer: A Randomized Controlled Trial.

Authors:  Yanfeng Hu; Changming Huang; Yihong Sun; Xiangqian Su; Hui Cao; Jiankun Hu; Yingwei Xue; Jian Suo; Kaixiong Tao; Xianli He; Hongbo Wei; Mingang Ying; Weiguo Hu; Xiaohui Du; Pingyan Chen; Hao Liu; Chaohui Zheng; Fenglin Liu; Jiang Yu; Ziyu Li; Gang Zhao; Xinzu Chen; Kuan Wang; Ping Li; Jiadi Xing; Guoxin Li
Journal:  J Clin Oncol       Date:  2016-02-22       Impact factor: 44.544

3.  Laparoscopy-assisted total gastrectomy with extended lymph node resection for advanced gastric cancer--reports of 82 cases.

Authors:  Jianjun Du; Jianyou Zheng; Yongqi Li; Jipeng Li; Gang Ji; Guanglong Dong; Zhi Yang; Weizhong Wang; Zhiqing Gao
Journal:  Hepatogastroenterology       Date:  2010 Nov-Dec

4.  Effect of comorbidities on postoperative complications in patients with gastric cancer after laparoscopy-assisted total gastrectomy: results from an 8-year experience at a large-scale single center.

Authors:  Jia-Bin Wang; Chao-Hui Zheng; Ping Li; Jian-Wei Xie; Jian-Xian Lin; Jun Lu; Qi-Yue Chen; Long-Long Cao; Mi Lin; Chang-Ming Huang
Journal:  Surg Endosc       Date:  2016-10-14       Impact factor: 4.584

5.  Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group.

Authors:  A Cuschieri; P Fayers; J Fielding; J Craven; J Bancewicz; V Joypaul; P Cook
Journal:  Lancet       Date:  1996-04-13       Impact factor: 79.321

6.  Poor survival rate in patients with postoperative intra-abdominal infectious complications following curative gastrectomy for gastric cancer.

Authors:  Masanori Tokunaga; Yutaka Tanizawa; Etsuro Bando; Taiichi Kawamura; Masanori Terashima
Journal:  Ann Surg Oncol       Date:  2012-10-18       Impact factor: 5.344

7.  Safety and curability of laparoscopic gastrectomy in elderly patients with gastric cancer.

Authors:  Shoji Shimada; Naruhiko Sawada; Sonoko Oae; Junichi Seki; Yojiro Takano; Yasuhiro Ishiyama; Kenta Nakahara; Chiyo Maeda; Eiji Hidaka; Fumio Ishida; Shin-Ei Kudo
Journal:  Surg Endosc       Date:  2018-03-30       Impact factor: 4.584

8.  Perioperative risk assessment for gastrectomy by surgical apgar score.

Authors:  Yuichiro Miki; Masanori Tokunaga; Yutaka Tanizawa; Etsuro Bando; Taiichi Kawamura; Masanori Terashima
Journal:  Ann Surg Oncol       Date:  2014-03-25       Impact factor: 5.344

Review 9.  Laparoscopic-assisted versus open radical gastrectomy for resectable gastric cancer: Systematic review, meta-analysis, and trial sequential analysis of randomized controlled trials.

Authors:  Hui-Zi Li; Jia-Xi Chen; Yang Zheng; Xiang-Nan Zhu
Journal:  J Surg Oncol       Date:  2016-04-13       Impact factor: 3.454

10.  The outcome of surgical treatment for elderly patients with gastric carcinoma.

Authors:  Katsunobu Sakurai; Kazuya Muguruma; Hisashi Nagahara; Kenjiro Kimura; Takahiro Toyokawa; Ryosuke Amano; Naoshi Kubo; Hiroaki Tanaka; Hiroshi Ohtani; Masakazu Yashiro; Kiyoshi Maeda; Masaichi Ohira; Kosei Hirakawa
Journal:  J Surg Oncol       Date:  2015-03-08       Impact factor: 3.454

View more
  1 in total

1.  Comparison of short-term efficacy between totally laparoscopic gastrectomy and laparoscopic assisted gastrectomy for elderly patients with gastric cancer.

Authors:  Rui-Yang Zhao; Hang-Hang Li; Ke-Cheng Zhang; Hao Cui; Huan Deng; Jing-Wang Gao; Bo Wei
Journal:  World J Gastrointest Surg       Date:  2022-09-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.